![logo](/logos/CBAY.webp)
CymaBay Therapeutics, Inc.
NASDAQ:CBAY
32.48 (USD) • At close March 21, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | CymaBay Therapeutics, Inc. |
Symbool | CBAY |
Munteenheid | USD |
Prijs | 32.48 |
Beurswaarde | 3,728,216,800 |
Dividendpercentage | 0% |
52-weken bereik | 7.261 - 32.5 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Sujal A. Shah |
Website | https://www.cymabay.com |
An error occurred while fetching data.
Over CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)